5-(2-Aminopyrimidin-4-yl)-2-(cyclobutylmethoxy)benzonitrile | 1419747-21-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-(2-Aminopyrimidin-4-yl)-2-(cyclobutylmethoxy)benzonitrile
• 英文别名: 5-(2-aminopyrimidin-4-yl)-2-(cyclobutylmethoxy)benzonitrile
• CAS: 1419747-21-9
• 化学式: C₁₆H₁₆N₄O
• 分子量: 280.329
• InChiKey: ADZXULSZFPRIOH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  84.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  5-bromo-2-cyclobutylmethoxybenzonitrile 在 四(三苯基膦)钯 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 potassium acetate 、 sodium carbonate 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 生成 5-(2-Aminopyrimidin-4-yl)-2-(cyclobutylmethoxy)benzonitrile
  参考文献：
  名称：

  Lead optimization of isocytosine-derived xanthine oxidase inhibitors

  摘要：

  We report our attempts at improving the oral efficacy of low-nanomolar inhibitors of xanthine oxidase from isocytosine series through chemical modifications. Our lead compound had earlier shown good in vivo efficacy when administered intraperitoneally but not orally. Several modifications are reported here which achieved more than twofold improvement in exposure. A compound with significant improvement in oral efficacy was also obtained. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.11.057

文献信息

• Lead optimization of isocytosine-derived xanthine oxidase inhibitors
  作者：Komal Bajaj、Sandeep Burudkar、Pranay Shah、Ashish Keche、Usha Ghosh、Prashant Tannu、Smriti Khanna、Ankita Srivastava、Nitin J. Deshmukh、Amol Dixit、Yogesh Ahire、Anagha Damre、Kumar V.S. Nemmani、Asha Kulkarni-Almeida、Chandrika B-Rao、Rajiv Sharma、H. Sivaramakrishnan

  DOI：10.1016/j.bmcl.2012.11.057

  日期：2013.2

  We report our attempts at improving the oral efficacy of low-nanomolar inhibitors of xanthine oxidase from isocytosine series through chemical modifications. Our lead compound had earlier shown good in vivo efficacy when administered intraperitoneally but not orally. Several modifications are reported here which achieved more than twofold improvement in exposure. A compound with significant improvement in oral efficacy was also obtained. (c) 2012 Elsevier Ltd. All rights reserved.